Induction Docetaxel/Cisplatin/5-fluorouracil (TPF) as Selector for Chemo Radiation Therapy (RT) Versus Partial Laryngectomy in Advanced Laryngeal Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Treatment of patients with one cycle of induction chemotherapy to select for organ preservation of the larynx has been proven as a standard approach. When compared to historical controls. The investigators propose to study patients with a similar treatment strategy (i.e. one cycle of induction chemotherapy followed by two more chemotherapy cycles, in advanced nodal disease, followed by chemoradiation for those responding to the initial chemotherapy. Those who fail to respond or fail in radiation will directly undergo surgery. The novelty of the proposed study is that non responders and failures will be given the opportunity of larynx preserving supracricoid laryngectomy. The investigators will attempt to reduce toxicity from induction chemotherapy and improve potency with the use of docetaxel/cisplatin/5-fluorouracil (TPF) in place of the standard regimen of cisplatin and 5-fluorouracil (PF). Emerging data demonstrates that induction regimens containing triplets with platinum, 5-fluorouracil, and taxanes produce higher response rates and less overall toxicity when compared to induction strategies utilizing PF
| Condition | Intervention | Phase |
|---|---|---|
|
Larynx Cancer |
Procedure: laryngoscopy Drug: Taxotere (Docetaxel), Cisplatin, 5FU |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase II Organ Preservation Trial Using Cisplatin Concomitant With Radiation Therapy in Advanced Laryngeal Cancer Patients Who Have Responded to Induction Chemotherapy With Taxotere, Cisplatin, and 5-Fluorouracil (TPF) |
- Improvement in larynx preservation free survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
- Improvement in overall survival in patients treated under this regimen in comparison to historical control [ Time Frame: 5 years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 100 |
| Study Start Date: | April 2010 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: larynx preservation
Decision between surgery and Chemo-rt according to response to initial induction chemotherapy
|
Procedure: laryngoscopy
Treatment of advanced larynx cancer with induction TPF, in order to decide between chemoradiation and laryngeal preservation surgery
Other Name: supracrocoid laryngectomy
Drug: Taxotere (Docetaxel), Cisplatin, 5FU
Taxotere 75 mg/m2 D1, Cisplatin 75 mg/m2 D1, 5FU 750 mg/m2 D1-4
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients must have pathologically confirmed previously untreated, resectable, squamous cell carcinoma of the larynx.
- Disease must be Stage III or IV.
- Tumor must be potentially surgically resectable and curable with conventional surgery and radiation therapy.
- Patients must undergo pre-treatment endoscopic tumor staging and CT scanning of chest and neck.(pet scan optional)
- Eastern Cooperative Oncology Group (ECOG) Performance status 0-2.
Pre-treatment laboratory criteria:
- WBC > 3500/ul, granulocyte > 1500/ul.
- Platelet count > 100,000/ul.
- Calculated or measured creatinine clearance > 60 cc/min.
- AST and ALT < 2.5 X ULN
- Patients must give documented informed consent to participate in this study.
Exclusion Criteria:
- Prior head and neck malignancy or active non-head and neck malignancy. Except for cured non-melanoma skin cancer,
- Prior head and neck radiation.
- Documented evidence of distant metastases.
- Active infection.
- Pregnancy or lactation. Patients must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy.
- Any medical or psychiatric illness which in the opinion of the principal investigator would compromise the patient's ability to tolerate this treatment.
- Age < 18 years.
- Patients with psychiatric/social situations that would limit compliance with study requirements are not eligible.
- Patients with Grade > 2 peripheral neuropathy.
- Any history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80.
Criteria for supracricoid resection for chemo selection non responders
Inclusion Criteria :
- At least one functional arytenoids (physical and radiological examinations)
- Involvement of thyroid cartilage including extrathyroid cartilage extension.
Exclusion criteria:
- Subglottic extension anteriorly.
- Pre epiglottic extension.
- Subglottic extension laterally.
- Interarytenoid involvement.
- Two Arytenoids involved.
Criteria for supracricoid resection for Chemoradiation failure:
Inclusion Criteria:
- At least one functional arytenoid (physical and radiological examinations)
- Involvement of thyroid cartilage (with no radiological evidence for extra thyroid Extension).
Exclusion Criteria:
- Extrathyroid cartilage extension.
- Involvement preepiglottic space.
- Subglottic extension.
- Interarytenoid involvement.
Contacts and Locations| Contact: Aron Popovtzer, md | 97239378044 | aronp@clalit.org.il |
| Contact: Raphael Feinmesser, md | 97239376453 | feinmesserr@clalit.org.il |
| Israel | |
| Rabin MC | Not yet recruiting |
| Petach Tikva, Israel, 49100 | |
| Contact: Aron Popovtzer, MD 039378004 aronp@clalit.org.il | |
| Contact: Salomon Stemmer, MD 039378023 sstemmer@clalit.org.il | |
| Principal Investigator: Aron Popovtzer, MD | |
| Principal Investigator: | Aron Popovtzer, MD | Rabin MC |
More Information
No publications provided
| Responsible Party: | Aron Popovtzer senior doctor, Rabin Medical Center |
| ClinicalTrials.gov Identifier: | NCT01073683 History of Changes |
| Other Study ID Numbers: | RMC5476 |
| Study First Received: | January 12, 2010 |
| Last Updated: | March 3, 2010 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Keywords provided by Rabin Medical Center:
|
TPF INDUCTION CHEMOTHERAPY LARYNX PRESERVATION SUPACRICOID LARYNGECTOMY Stage 3 and 4 larynx cancer |
Additional relevant MeSH terms:
|
Laryngeal Neoplasms Otorhinolaryngologic Neoplasms Head and Neck Neoplasms Neoplasms by Site Neoplasms Laryngeal Diseases Respiratory Tract Diseases Respiratory Tract Neoplasms Otorhinolaryngologic Diseases Docetaxel Cisplatin |
Fluorouracil Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Radiation-Sensitizing Agents Physiological Effects of Drugs Antimetabolites Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Immunosuppressive Agents Immunologic Factors |
ClinicalTrials.gov processed this record on May 21, 2013